Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FENC 
Fennec Pharmaceuticals Inc (FENC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: FENC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $14
1 Year Target Price $14
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.03% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 251.46M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 5 | Beta 0.4 | 52 Weeks Range 3.96 - 9.42 | Updated Date 08/29/2025 |
52 Weeks Range 3.96 - 9.42 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.04 | Actual -0.11 |
Profitability
Profit Margin -36.15% | Operating Margin (TTM) -28.31% |
Management Effectiveness
Return on Assets (TTM) -11.19% | Return on Equity (TTM) -1005.59% |
Valuation
Trailing PE - | Forward PE 11.93 | Enterprise Value 253075062 | Price to Sales(TTM) 7.55 |
Enterprise Value 253075062 | Price to Sales(TTM) 7.55 | ||
Enterprise Value to Revenue 7.6 | Enterprise Value to EBITDA 20.27 | Shares Outstanding 27831700 | Shares Floating 14616929 |
Shares Outstanding 27831700 | Shares Floating 14616929 | ||
Percent Insiders 16.13 | Percent Institutions 57.88 |
Upturn AI SWOT
Fennec Pharmaceuticals Inc
Company Overview
History and Background
Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for cancer. Founded to address unmet medical needs in oncology, Fennec's primary focus has been on developing a product to prevent ototoxicity caused by platinum-based chemotherapy.
Core Business Areas
- Pharmaceutical Development: Focused on the development and commercialization of therapies for cancer, particularly in the area of ototoxicity prevention.
Leadership and Structure
Rostislav Raykov serves as the Chief Executive Officer and President. The company has a board of directors overseeing strategic direction.
Top Products and Market Share
Key Offerings
- PEDMARK: PEDMARK (sodium thiosulfate) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month to < 18 years of age with localized, non-metastatic solid tumors. The market share for PEDMARK is growing, but the overall market for ototoxicity prevention is relatively new. Competitors are primarily institutions or other companies researching alternative methods of ototoxicity prevention, though PEDMARK is the only approved treatment. Revenue data can be found in their quarterly and annual reports.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, particularly in the oncology space. There is significant demand for therapies that reduce the side effects of cancer treatments. Significant growth is also projected due to growing patient populations and technological advancements.
Positioning
Fennec Pharmaceuticals is positioned as a leader in the ototoxicity prevention space, with PEDMARK being the only FDA-approved product for this indication.
Total Addressable Market (TAM)
The TAM for ototoxicity prevention in pediatric cancer patients is estimated to be significant, potentially reaching hundreds of millions of dollars annually. Fennec's position with PEDMARK allows them to capture a substantial share of this market.
Upturn SWOT Analysis
Strengths
- FDA-approved product (PEDMARK)
- First-mover advantage in ototoxicity prevention
- Focused pipeline on specific unmet need
Weaknesses
- Single-product company
- Reliance on successful commercialization of PEDMARK
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Expanding PEDMARK's label to other patient populations
- Developing new therapies for related oncology side effects
- Potential for partnerships or acquisitions
Threats
- Competition from alternative ototoxicity prevention methods
- Regulatory hurdles
- Potential for generic versions of PEDMARK in the future
Competitors and Market Share
Key Competitors
Competitive Landscape
Since PEDMARK is the only FDA-approved drug, there are no direct competitors. However, indirect competitors include companies working on different strategies to prevent ototoxicity.
Growth Trajectory and Initiatives
Historical Growth: Fennec's historical growth is tied to the development and approval of PEDMARK.
Future Projections: Future growth depends on successful commercialization of PEDMARK, expansion into new markets, and potential development of new therapies. Analyst estimates should be consulted for specific financial projections.
Recent Initiatives: Focus on commercial launch and market penetration of PEDMARK.
Summary
Fennec Pharmaceuticals is a biopharmaceutical company with the only FDA approved medication for ototoxicity prevention. PEDMARK is it's only product so the company relies heavily on this for their revenue. They will continue to pursue this area of need, but may struggle if they do not find other medications to add to their portfolio. The company needs to grow it's sales and continue to innovate to stay competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Fennec Pharmaceuticals Inc. SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fennec Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 2001-06-05 | CEO & Director Mr. Jeffrey S. Hackman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://fennecpharma.com |
Full time employees 32 | Website https://fennecpharma.com | ||
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.